235 related articles for article (PubMed ID: 22744210)
1. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host.
Zhang Z; Hu Z; Gupta J; Krimmel JD; Gerseny HM; Berg AF; Robbins JS; Du H; Prabhakar B; Seth P
Cancer Gene Ther; 2012 Sep; 19(9):630-6. PubMed ID: 22744210
[TBL] [Abstract][Full Text] [Related]
2. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model.
Hu Z; Zhang Z; Guise T; Seth P
Hum Gene Ther; 2010 Nov; 21(11):1623-9. PubMed ID: 20712434
[TBL] [Abstract][Full Text] [Related]
3. Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model.
Hu Z; Gupta J; Zhang Z; Gerseny H; Berg A; Chen YJ; Zhang Z; Du H; Brendler CB; Xiao X; Pienta KJ; Guise T; Lee C; Stern PH; Stock S; Seth P
Hum Gene Ther; 2012 Aug; 23(8):871-82. PubMed ID: 22551458
[TBL] [Abstract][Full Text] [Related]
4. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy.
Hu Z; Robbins JS; Pister A; Zafar MB; Zhang ZW; Gupta J; Lee KJ; Newman K; Yun CO; Guise T; Seth P
Cancer Gene Ther; 2010 Apr; 17(4):235-43. PubMed ID: 19798122
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer.
Hu Z; Gerseny H; Zhang Z; Chen YJ; Berg A; Zhang Z; Stock S; Seth P
Mol Ther; 2011 Sep; 19(9):1609-18. PubMed ID: 21712815
[TBL] [Abstract][Full Text] [Related]
6. Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.
Xu W; Zhang Z; Yang Y; Hu Z; Wang CH; Morgan M; Wu Y; Hutten R; Xiao X; Stock S; Guise T; Prabhakar BS; Brendler C; Seth P
Mol Ther; 2014 Aug; 22(8):1504-1517. PubMed ID: 24791939
[TBL] [Abstract][Full Text] [Related]
7. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
Seth P; Wang ZG; Pister A; Zafar MB; Kim S; Guise T; Wakefield L
Hum Gene Ther; 2006 Nov; 17(11):1152-60. PubMed ID: 17032151
[TBL] [Abstract][Full Text] [Related]
8. LyP-1-Modified Oncolytic Adenoviruses Targeting Transforming Growth Factor β Inhibit Tumor Growth and Metastases and Augment Immune Checkpoint Inhibitor Therapy in Breast Cancer Mouse Models.
Xu W; Yang Y; Hu Z; Head M; Mangold KA; Sullivan M; Wang E; Saha P; Gulukota K; Helseth DL; Guise T; Prabhkar BS; Kaul K; Schreiber H; Seth P
Hum Gene Ther; 2020 Aug; 31(15-16):863-880. PubMed ID: 32394753
[TBL] [Abstract][Full Text] [Related]
9. Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases.
Yang Y; Xu W; Neill T; Hu Z; Wang CH; Xiao X; Stock SR; Guise T; Yun CO; Brendler CB; Iozzo RV; Seth P
Hum Gene Ther; 2015 Dec; 26(12):813-25. PubMed ID: 26467629
[TBL] [Abstract][Full Text] [Related]
10. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
[TBL] [Abstract][Full Text] [Related]
11. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.
Zhang Z; Krimmel J; Zhang Z; Hu Z; Seth P
Hum Gene Ther; 2011 Sep; 22(9):1137-42. PubMed ID: 21480822
[TBL] [Abstract][Full Text] [Related]
12. An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: in vitro evaluation.
Wang ZG; Zhao W; Ramachandra M; Seth P
Mol Cancer Ther; 2006 Feb; 5(2):367-73. PubMed ID: 16505111
[TBL] [Abstract][Full Text] [Related]
13. [A recombinant adeno-associated virus expressing secretory TGF-β type Ⅱ receptor inhibits triple-negative murine breast cancer 4T1 cell proliferation and lung metastasis in mice].
Cui Z; Ma C; Wang Q; Chen J; Yan Z; Yang J; Lü Y; Cao C
Nan Fang Yi Ke Da Xue Xue Bao; 2024 May; 44(5):818-826. PubMed ID: 38862439
[TBL] [Abstract][Full Text] [Related]
14. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
15. The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer.
Xu W; Neill T; Yang Y; Hu Z; Cleveland E; Wu Y; Hutten R; Xiao X; Stock SR; Shevrin D; Kaul K; Brendler C; Iozzo RV; Seth P
Gene Ther; 2015 Mar; 22(3):247-56. PubMed ID: 25503693
[TBL] [Abstract][Full Text] [Related]
16. In vivo safety, biodistribution and antitumor effects of uPAR retargeted oncolytic measles virus in syngeneic cancer models.
Jing Y; Zaias J; Duncan R; Russell SJ; Merchan JR
Gene Ther; 2014 Mar; 21(3):289-97. PubMed ID: 24430235
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice.
Dai S; Lv Y; Xu W; Yang Y; Liu C; Dong X; Zhang H; Prabhakar BS; Maker AV; Seth P; Wang H
Cancer Gene Ther; 2020 Dec; 27(12):923-933. PubMed ID: 32307442
[TBL] [Abstract][Full Text] [Related]
18. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
Jing Y; Bejarano MT; Zaias J; Merchan JR
Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
[TBL] [Abstract][Full Text] [Related]
19. An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast cancer.
Rausch MP; Hahn T; Ramanathapuram L; Bradley-Dunlop D; Mahadevan D; Mercado-Pimentel ME; Runyan RB; Besselsen DG; Zhang X; Cheung HK; Lee WC; Ling LE; Akporiaye ET
Anticancer Res; 2009 Jun; 29(6):2099-109. PubMed ID: 19528470
[TBL] [Abstract][Full Text] [Related]
20. The safety and efficacy of systemic delivery of a new liver-de-targeted TGFβ signaling inhibiting adenovirus in an immunocompetent triple negative mouse mammary tumor model.
Shin SC; Vickman RE; Filimon B; Yang Y; Hu Z; Mangold KA; Prabhakar BS; Schreiber H; Xu W
Cancer Gene Ther; 2024 Apr; 31(4):574-585. PubMed ID: 38267626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
